<DOC>
	<DOCNO>NCT01851447</DOCNO>
	<brief_summary>Background : - Some kind muscular dystrophy affect skeletal muscle membrane . In condition , muscle membrane fragile . This affect muscle contract relax , cause movement problem . Researchers look several muscle enzyme , chemical affect muscle cell function . By study change enzymes , may able good understand muscular dystrophy affect cell . Researchers want collect biomarkers ( chemical blood sample ) people fragile sarcolemmal muscular dystrophy . This information may provide good treatment condition . Objectives : - To study biomarkers may affect muscle people fragile sarcolemmal muscular dystrophy . Eligibility : - Individuals least 18 year age fragile sarcolemmal muscular dystrophy . Design : - Participants screen medical history physical exam . - Participants ask come four visit National Institutes Health Clinical Center . The visit least 2 month apart . Each visit require participant stay 5 day clinical center . - During visit , participant provide frequent small blood sample . These sample collect rest physical exercise . - Participants also physical therapy assessment . They perform standard motor function test image test ( MRI , MRS ) . These test may take 1 hour time . - Treatment provide part study .</brief_summary>
	<brief_title>Skeletal Muscle Biomarkers People With Fragile Sarcolemmal Muscular Dystrophy</brief_title>
	<detailed_description>Objectives : aim protocol identify biomarker clinical correlate change barrier function skeletal muscle membrane ( i.e . cell membrane permeability ) routine motor function test patient one Fragile Sarcolemmal Muscular Dystrophies ( FSMD ) . Study population : patient early adulthood later onset FSMD ( LGMD2B-F , I , L , MM , BMD , MMD3 ) . Design : pilot study . Outcome measure : increase change baseline level protein release blood damage skeletal muscle , creatine kinase ( CK ) , lactate dehydrogenase ( LDH ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , troponins , myoglobin serum , change inflammation marker , circulate microRNAs image study identify effective biomarkers use future clinical trial .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<criteria>INCLUSION CRITERIA : Aged 18 old Have confirm genetic diagnosis one FSMDs clinical phenotype consistent one FSMDs Be able travel NIH Clinical Center NIH study Able commit multiple 5 day stay NIH Clinical Center Established primary care physician Ambulant : able walk 10 meter 33 foot without walk aid orthotics EXCLUSION CRITERIA : Fail meet inclusion criterion Are unable unwilling examine Adults unable provide consent Have active , ongoing medical problem ( e.g . diabetes , hypothyroidism , pancreatitis , anemia , cancer , renal , hepatic , Pulmonary cardiac disease ) undergone recent surgery ( i.e . le 8 day postsurgery ) Pregnant female Currently take combination antiinflammatory drug , statin drug know myotoxicity , narcotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 22, 2017</verification_date>
	<keyword>Muscle</keyword>
	<keyword>Inflammatory Cytokines</keyword>
	<keyword>Exercise</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Predictors Outcome</keyword>
</DOC>